UK Fibroscan Market Research Report By Technology (Vibration-controlled Transient Electrography (VCTE), Controlled Attenuation Parameter (CAP), Others), By Modality (Portable, Non-Portable/Standalone), By Application (Hepatitis B or C, Nonalcoholic Fatty Liver Disease, Alcohol-related Liver Problems, Hemochromatosis, Others) and By End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Others)- Forecast to 2035

UK Fibroscan Market Overview

As per MRFR analysis, the UK Fibroscan Market Size was estimated at 4.66 (USD Billion) in 2024.The UK Fibroscan Market Industry is expected to grow from 4.89(USD Billion) in 2025 to 8.87 (USD Billion) by 2035. The UK Fibroscan Market CAGR (growth rate) is expected to be around 5.563% during the forecast period (2025 - 2035)

Key UK Fibroscan Market Trends Highlighted

The UK Fibroscan market is experiencing significant trends driven largely by the rising prevalence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and hepatitis. This trend is propelling demand for non-invasive diagnostic tools like Fibroscan, which offers quicker and less painful alternatives to traditional biopsy methods. As awareness of liver health increases among both healthcare providers and patients, more emphasis is being placed on early diagnosis and management, contributing to the market's growth. 

The National Health Service (NHS) in the UK has also been focusing on improving liver disease outcomes, which aligns with the increased adoption of Fibroscan technology in clinical settings. Opportunities in the UK Fibroscan market hinge on advancing technology and expanding clinical applications. Innovations in the accuracy and efficiency of Fibroscan devices lead to improved patient outcomes and have the potential to attract more healthcare providers. Additionally, increasing collaborations among government bodies, healthcare providers, and technology developers could further enhance the accessibility of Fibroscan services across the UK, particularly in underserved regions. 

Recent trends indicate a growing demand for training healthcare professionals on the use of Fibroscan technology. Tailored training programs could enhance the user experience and improve diagnosis rates.Furthermore, partnerships with community organizations focused on liver health can promote awareness and education, thus broadening the reach of Fibroscan services. The integration of telemedicine also plays a crucial role as healthcare systems adapt to remote monitoring solutions, making it more feasible for patients to receive liver assessments from home. 

Overall, the UK Fibroscan market is poised for growth driven by these evolving trends and opportunities that cater to the country's healthcare needs.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

UK Fibroscan Market Drivers

Increasing Prevalence of Liver Diseases

The growing incidence of liver diseases, particularly Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Liver Disease (ALD), is a significant driver for the UK Fibroscan Market Industry. According to the UK's National Health Service (NHS), liver diseases have risen by 400% since the 1970s, making them the third leading cause of premature death in the UK. With the UK population's increase in obesity rates, projected to reach 35% by 2030 per the UK government's Health Survey, the demand for advanced detection methods like Fibroscan, which provides a non-invasive assessment of liver stiffness and fat content, is expected to surge.

Organizations such as the British Liver Trust advocate for awareness and research, further pushing the need for innovative diagnostic tools in this sector. This symptomatology creates a ripe environment for the UK Fibroscan Market, propelling growth as healthcare sectors prioritize early diagnosis.

Technological Advancements in Medical Devices

The continuous innovation in medical technologies significantly drives the UK Fibroscan Market Industry. Groundbreaking advancements in ultrasound elastography, which Fibroscan utilizes, have enhanced the accuracy and efficiency of liver disease diagnostics. The UK is home to numerous biomedical companies, such as Echosens and GE Healthcare, which are at the forefront of this technological evolution. 

Reports from the UK government suggest that investment in medical technology has grown, with the sector generating approximately 21 billion USD in revenue annually.As these technologies evolve, so does their adoption rate within the healthcare framework, increasing access to Fibroscan machines in hospitals and clinics across the UK.

Government Initiatives and Health Policies

Government actions and health policies targeted at reducing the burden of liver diseases serve as a significant driver for the UK Fibroscan Market Industry. The UK government has launched several initiatives aimed at increasing screening and early diagnosis of liver-related illnesses. For instance, the NHS Long Term Plan emphasizes improved liver disease care, mandating increased availability of diagnostic tools, including Fibroscan, across healthcare facilities.

Allocations of greater than 2 billion USD over the next 5 years for preventive healthcare programs have supported this strategic focus, allowing healthcare providers to self-equip with diagnostic devices like Fibroscan, which accelerates the 5-year plan. The increase in availability of Fibroscan devices creates favorable market growth.

UK Fibroscan Market Segment Insights

Fibroscan Market Technology Insights

The UK Fibroscan Market, particularly in the Technology segment, reflects a focused advancement driven by innovations in hepatic diagnostics and non-invasive techniques. The overall growth in this market is supported by the increasing prevalence of liver diseases and a growing awareness of the need for accurate liver assessment tools. Within this segment, Vibration-controlled Transient Electrography (VCTE) has emerged as a critical technology for assessing liver stiffness, offering a reliable and non-invasive method that has garnered substantial clinical adoption due to its accuracy. The VCTE technology enjoys a prominent position within the market, as it bridges the gap between traditional invasive procedures and advanced diagnostic needs, enabling healthcare professionals to achieve precise evaluations of liver congestion and fibrosis.

Moreover, the Controlled Attenuation Parameter (CAP), which measures the degree of hepatic steatosis, is equally important in the overall landscape. Its ability to deliver comprehensive insights regarding fat accumulation in the liver further empowers clinicians by guiding them in tailoring therapeutic strategies, enhancing patient outcomes. As liver fat is a major contributor to chronic liver diseases, the CAP technology's significance cannot be understated, as it facilitates early detection and management of such conditions. Additionally, other advancements in the Fibroscan Market technology segment highlight the continuous evolution of diagnostic methodologies that aim for greater efficiencies and patient-centric approaches.

Overall, the Technology segment of the UK Fibroscan Market encompasses a range of innovations that align with the increasing demand for non-invasive solutions. This evolution is primarily fueled by advancements in imaging techniques and technologies developed to enhance the accuracy and reliability of liver disease assessments. As medical professionals seek to streamline diagnosis and treatment pathways, the segment's offerings hold significant promise, positioning them as integral components of modern healthcare practices in the UK. The sustained investment and efforts in this arena are indicative of the ongoing commitment to improving liver health diagnostics, paving the way for enhanced patient management strategies.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Fibroscan Market Modality Insights

The Modality segment of the UK Fibroscan Market reveals a diverse landscape with both Portable and Non-Portable/Standalone units playing crucial roles in fostering accessibility and efficiency in liver health assessment. Portable devices are gaining traction due to their ability to facilitate point-of-care testing, thereby enabling healthcare providers to offer quick evaluations directly to patients without the constraints of traditional settings. This is particularly relevant in rural and underserved areas of the UK, where access to specialized medical equipment can be limited.On the other hand, Non-Portable units are often deployed in hospitals and clinics equipped with advanced technology, providing comprehensive diagnostic capabilities and extensive patient data management. 

Together, these modalities address the rising demand for liver disease management solutions, contributing to the overall UK Fibroscan Market revenue growth and aligning with current healthcare objectives aimed at early diagnosis and intervention. The increasing prevalence of liver diseases, coupled with the push for more personalised healthcare, underscores the significance of both Portable and Non-Portable/Standalone modalities in enhancing patient outcomes across the UK’s healthcare landscape.

Fibroscan Market Application Insights

The Application segment of the UK Fibroscan Market encompasses critical areas of liver health, significantly addressing conditions such as Hepatitis B or C, Nonalcoholic Fatty Liver Disease (NAFLD), Alcohol-related Liver Problems, Hemochromatosis, and other related disorders. Hepatitis remains a public health challenge in the UK, demanding efficient diagnostic tools such as Fibroscan for monitoring liver stiffness and guiding treatment decisions. Nonalcoholic Fatty Liver Disease is on the rise, correlating with increasing obesity rates, thus emphasizing the need for effective screening methods to prevent progression to more severe liver diseases.

Alcohol-related Liver Problems continue to pose a significant burden on healthcare, necessitating robust assessment techniques to manage liver damage. Hemochromatosis, often underdiagnosed, benefits from early detection facilitated by Fibroscan, which provides non-invasive evaluations. Collectively, these areas represent a vital aspect of the UK Fibroscan Market segmentation, driven by the urgent need for improved liver health management and the growing prevalence of chronic liver diseases, influencing market growth and development trends. Advances in technology and increasing awareness among healthcare providers further bolster the demand for accurate and timely assessments in these applications.

Fibroscan Market End-user Insights

The End-user segment of the UK Fibroscan Market reflects a diverse landscape that is critical for delivering effective non-invasive liver diagnostic solutions. Hospitals and Clinics account for a significant share, as they are key players in providing immediate patient care and diagnostic services, where Fibroscan technology aids in assessing liver fibrosis. Diagnostic Centers also dominate this segment due to their specialized focus on imaging and diagnostics, which enhances early detection of liver diseases. 

Furthermore, Ambulatory Surgical Centers represent a growing segment, fostering patient convenience and quick turnaround for procedures involving Fibroscan.The segment classified as Others includes various healthcare institutions that play supportive roles in the overall ecosystem. As liver diseases continue to rise in the UK, driven by factors like obesity and alcohol consumption, the demand for reliable diagnostics in these End-user segments is expected to grow. Trends towards outpatient care and advancements in Fibroscan technology signify lucrative opportunities for operators within this realm, ultimately aiming to improve patient outcomes and healthcare efficiency.

UK Fibroscan Market Key Players and Competitive Insights

The UK Fibroscan Market is characterized by a competitive landscape that is shaped by several key players focusing on advanced technologies and innovative solutions for liver health assessment. This market is witnessing significant growth due to the increasing prevalence of liver diseases, coupled with a growing awareness of non-invasive diagnostic tools. Competitive insights in this market indicate a trend toward the development of enhanced Fibroscan devices that improve accuracy, speed, and patient comfort. Participants in this market are striving to differentiate themselves through technology advancements, partnerships, and service offerings catering to various healthcare settings. 

The landscape is dynamic as companies seek to expand their market share by addressing the needs of healthcare professionals and patients alike through improved diagnostics and therapeutic options.Echosens holds a prominent position in the UK Fibroscan Market owing to its pioneering role in developing non-invasive liver assessment technologies. The company's Fibroscan devices are recognized for their superior accuracy and reliability in estimating liver stiffness and fat content, contributing to effective liver disease management. Echosens has established significant partnerships with healthcare institutions, facilitating the penetration of its Fibroscan technology in various clinical settings across the UK. 

The company has also focused on enhancing user experience and patient comfort, which strengthens its market presence. By continually investing in research and development, Echosens underscores its commitment to delivering cutting-edge solutions to address the evolving needs of liver healthcare in the UK.Accuhealth, another key player in the UK Fibroscan Market, offers a comprehensive range of diagnostic solutions aimed at promoting better liver health. The company specializes in providing Fibroscan devices that utilize innovative approaches to deliver accurate and timely results. Accuhealth's strong market presence is supported by strategic partnerships and collaborations with healthcare providers, which have allowed for broader accessibility to their products. 

The strengths of Accuhealth lie in its dedication to customer service and continuous product enhancements, which have helped it maintain a competitive edge. Recently, the company has engaged in various mergers and acquisitions aimed at expanding its portfolio and enhancing its technological capabilities, solidifying its standing in the competitive UK Fibroscan Market. Through these strategies, Accuhealth is well-positioned to address the growing demand for reliable liver diagnostic tools in the region.

Key Companies in the UK Fibroscan Market Include

• Echosens


• Accuhealth


• Fujifilm


• GE Healthcare


• Bracco Imaging


• Hitachi Medical Systems


• Philips


• Agfa Healthcare


• Mindray


• Konica Minolta


• Boehringer Ingelheim


• Hologic


• Canon Medical Systems


• Siemens Healthineers


• Samsung Medison

UK Fibroscan Market Industry Developments

Recent developments in the UK Fibroscan Market have been notable, particularly with advancements in technologies offered by companies like Echosens and Philips, which continue to enhance non-invasive liver assessment methods. In August 2023, Echosens launched an upgraded version of its Fibroscan device, incorporating artificial intelligence functionalities that improve diagnostic accuracy, which has generated significant interest across healthcare institutions in the UK. Companies such as GE Healthcare and Fujifilm are also engaged in competitive strategy enhancement to maintain market relevance. Noteworthy is Bracco Imaging's collaboration with Hitachi Medical Systems focused on integrating imaging modalities to broaden diagnostic capabilities within the market. 

In terms of mergers and acquisitions, there has been no recent major activity reported among the key players in this sector, such as Siemens Healthineers and Canon Medical Systems. The overall market valuation for Fibroscan technologies has seen an upward trend due to increasing prevalence of liver diseases in the UK, driving demand for safer, non-invasive diagnostic techniques. This growth trajectory is supported by government initiatives focusing on improving liver health management strategies, which is crucial given the rising health burden associated with liver conditions in the UK.

UK Fibroscan Market Segmentation Insights

• 
  Fibroscan Market Technology Outlook
  
  
  
  • Vibration-controlled Transient Electrography (VCTE)
  
  
  
  
  • Controlled Attenuation Parameter (CAP)
  
  
  • Others
  
  


• 
  Fibroscan Market Modality Outlook
  
  
  
  • Portable
  
  
  
  
  • Non-Portable/Standalone
  
  


• 
  Fibroscan Market Application Outlook
  
  
  
  • Hepatitis B or C
  
  
  
  
  • Nonalcoholic Fatty Liver Disease
  
  
  • Alcohol-related Liver Problems
  
  
  • Hemochromatosis
  
  
  • Others
  
  


• 
  Fibroscan Market End-user Outlook
  
  
  
  • Hospitals & Clinics
  
  
  
  
  • Diagnostic Centers
  
  
  • Ambulatory Surgical Centers
  
  
  • Others
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	4.66(USD Billion)
MARKET SIZE 2024	4.89(USD Billion)
MARKET SIZE 2035	8.87(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.563% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Echosens, Accuhealth, Fujifilm, GE Healthcare, Bracco Imaging, Hitachi Medical Systems, Philips, Agfa Healthcare, Mindray, Konica Minolta, Boehringer Ingelheim, Hologic, Canon Medical Systems, Siemens Healthineers, Samsung Medison
SEGMENTS COVERED	Technology, Modality, Application, End-user
KEY MARKET OPPORTUNITIES	Growing prevalence of liver diseases, Increasing demand for non-invasive diagnostics, Advancements in Fibroscan technology, Rising awareness of liver health, Expansion in healthcare facilities access
KEY MARKET DYNAMICS	increasing prevalence of liver diseases, technological advancements in diagnostics, growing awareness among healthcare providers, favorable reimbursement policies, rising investment in healthcare infrastructure
COUNTRIES COVERED	UK